The global plasma fractionation market is projected to reach USD 29.50 Billion by 2023 from USD 21.23 Billion in 2018, at a CAGR of 6.8% during the forecast period. The global plasma fractionation market is consolidated in nature, with top the four players accounting for 60–65% share of the market. In 2017, CSL (Australia), Grifols (Spain), Shire (Ireland), and Octapharma (Switzerland) dominated the plasma fractionation market. These players together accounted for a share of 61.4%.
CSL (Australia) dominated the plasma fractionation market in 2017. The company’s dominance in the market can be attributed to its diversified product portfolio, which includes a wide range of plasma products for bleeding disorders, neurological diseases, and immune diseases. The company has strong manufacturing and distribution capabilities, which enables it to serve customers across 30 countries with more than 170 plasma collection centers across the US and Europe.
Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=93798284
Shire (Ireland) was ranked third in the plasma fractionation market in 2017. The company has 12 manufacturing facilities and distributes products in more than 100 countries. The company has 80 plasma collection facilities in 24 states of the US and at 7 locations in Austria. To increase plasma fractionation capacity, the company focuses on expanding new plasma donation centers. In this regard, in February 2016, Baxalta, a subsidiary of Shire opened a new plasma collection center in Gwinnett to increase plasma collection.
In recent years, the company has emphasized strengthening its plasma product portfolio for various acute and chronic diseases through external innovation, acquisitions, asset purchases, in-licensing transactions, development, supply and distribution agreements, and other strategic partnerships, which will be complemented by ongoing internal R&D efforts. For instance, in January 2016, the company entered into a strategic collaboration with Symphogen A/S (Denmark) to build an innovative portfolio of immunotherapies.
